Cannabis and Mood Disorders

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Purpose of review

The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders.

Recent findings

Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor are the putative therapeutic effects of cannabis use, or its components delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in these illnesses. The evidence surrounding treatments for patients with this comorbidity is lacking, with more support for psychotherapeutic treatments compared with pharmacological treatments.

Summary

Cannabis use may be associated mood disorders, but more research is needed to increase our understanding of the mechanisms for this association, and to develop more effective treatments for this comorbidity.

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 101623508

Journal ID (pubmed-jr-id): 42136

Journal ID (nlm-ta): Curr Addict Rep

Journal ID (iso-abbrev): Curr Addict Rep

Title: Current addiction reports

ISSN (Electronic): 2196-2952

Publication date Nihms-submitted: 10 May 2018

Publication date (Electronic): 10 May 2018

Publication date (Print): September 2018

Publication date PMC-release: 01 September 2019

Volume: 5

Issue: 3

Pages: 336-345

Affiliations

[1 ]Addictions Division, Centre for Addictions and Mental Health (CAMH), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA USA

[2 ]Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA USA

[3 ]Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON Canada

Author notes

Address for Correspondence: Tony P. George, MD, FRCPC, Professor of Psychiatry, University of Toronto, Chief, Addictions Division, CAMH, 100 Stokes Street, BGB 3288, Toronto, ON Canada MJ6 1H4, Tel: (416) 535-8501 x32662, Fax: (416) 260-4171, tony.george@ 123456camh.ca

Article

Accession ID: PMC6329464 Pmcid ID: PMC6329464 Pmc-uid ID: 6329464 Manuscript ID: nihpa967005

DOI: 10.1007/s40429-018-0214-y

PMC ID: 6329464

PubMed ID: 30643708

SO-VID: 61f5a4d4-71fe-4b7d-8f04-288d1d061b77

History

Comments

Comment on this article

scite_

Cited by 16

See all cited by